Targeted Centyrin-siRNA Silencing of IFIH1/MDA5 Improves Disease Outcomes in a Preclinical Type I Diabetes Model

Kate Palozola, PhD, is the biology team leader at Aro Biotherapeutics, where she advances siRNA therapeutics from discovery through early preclinical development. She focuses on translating target biology into actionable programs, leading in vitro and invivo proof-of-concept across multiple indications and contributing to platform development. She has contributed to multiple publications and IND-enabling programs.